Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONYCR2
- Development stage
- Phase 2
- Lead developer
- Onyvax
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Intradermal
01
Overview
ONYCR2 is an allogeneic adenocarcinoma cell-based vaccine developed by Onyvax. It is being investigated in a Phase I/II clinical trial for the treatment of locally advanced or metastatic colorectal cancer. As a cell-based vaccine, its mechanism involves stimulating the body's immune system to recognize and kill colorectal tumor cells.
Beyond the preview
Go deeper on ONYCR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONYCR2.